【结 构 式】 |
【药物名称】RPR-132703 【化学名称】2-Cyclopropyl-7-(3,5-dimethylpyridin-4-ylmethoxy)-4-methoxy-1H-benzimidazole 【CA登记号】201285-86-1 【 分 子 式 】C19H21N3O2 【 分 子 量 】323.39812 |
【开发单位】Aventis Pharma (Originator) 【药理作用】Antiarthritic Drugs, ANTIINFECTIVE THERAPY, Asthma Therapy, Bronchodilators, RESPIRATORY DRUGS, TREATMENT OF MUSCULOSKELETAL & CONNECTIVE TISSUE DISEASES, Treatment of Septic Shock, Phosphodiesterase IV Inhibitors, TNF-alpha Antagonists |
合成路线1
Condensation of methyl 3-amino-4-methoxybenzoate (I) with cyclopropyl cyanide (II) in the presence of p-toluenesulfonic acid at 180 C gave amidine (III). Subsequent reaction of (III) with sodium hypochlorite in methanolic HCl, followed by treatment of the intermediate chloroimine with aqueous Na2CO3, furnished the benzimidazole (IV). The ester group of (IV) was reduced to alcohol (V) with DIBAL-H, and then oxidized to aldehyde (VI) using activated MnO2. Protection of the imidazole N-H of (VI) was effected by means of 2-(trimethylsilyl)ethoxymethyl chloride (VII) and NaH to afford the 1-(2-trimethylsilyl)ethoxymethylimidazole (VIII) accompanied by some amounts of the 3-substituted analogue. The Baeyer-Villiger rearrangement of the formyl group employing m-chloroperbenzoic acid then produced phenol (IX), together with the 3-protected imidazole. The pyridylmethanol derivative (XIII) was obtained from 4-nitro-3,5-dimethylpyridine N-oxide (X) through conversion to the bromopyridine (XI) with PBr3, followed by lithium-halogen exchange and condensation with DMF to give aldehyde (XII), and then reduction of (XII) with NaBH4 to (XIII). Condensation of the hydroxybenzimidazole (IX) with pyridylmethanol (XIII) using diisopropylazodicarboxylate and triphenylphosphine gave ether (XIV), which was finally deprotected with HCl in boiling aqueous methanol to yield the target compound.
【1】 Cox, P.J.; Bower, S.; Aldous, D.J.; Astles, P.C.; McGarry, D.G.; Hulme, C.; Regan, J.R.; Huang, F.-C.; Djuric, S.W.; Moriarty, K.J.; Mathew, R.M.; Poli, G.B. (Aventis Pharma SA); Substd. azabicyclic cpds. and their use as inhibitors of the production of TNF and cyclic AMP phosphodiesterase. EP 0934307; JP 2000509719; WO 9748697 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 25130 | methyl 3-amino-4-methoxybenzoate | 24812-90-6 | C9H11NO3 | 详情 | 详情 |
(II) | 27238 | cyclopropanecarbonitrile | 5500-21-0 | C4H5N | 详情 | 详情 |
(III) | 27239 | methyl 3-[[cyclopropyl(imino)methyl]amino]-4-methoxybenzoate | C13H16N2O3 | 详情 | 详情 | |
(IV) | 27240 | methyl 2-cyclopropyl-4-methoxy-1H-benzimidazole-7-carboxylate | C13H14N2O3 | 详情 | 详情 | |
(V) | 27241 | (2-cyclopropyl-4-methoxy-1H-benzimidazol-7-yl)methanol | C12H14N2O2 | 详情 | 详情 | |
(VI) | 27242 | 2-cyclopropyl-4-methoxy-1H-benzimidazole-7-carbaldehyde | C12H12N2O2 | 详情 | 详情 | |
(VII) | 27243 | [2-(chloromethoxy)ethyl](trimethyl)silane | 76513-69-4 | C6H15ClOSi | 详情 | 详情 |
(VIII) | 27244 | 2-cyclopropyl-4-methoxy-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazole-7-carbaldehyde | C18H26N2O3Si | 详情 | 详情 | |
(IX) | 27245 | 2-cyclopropyl-4-methoxy-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-7-ol | C17H26N2O3Si | 详情 | 详情 | |
(X) | 27246 | 3,5-dimethyl-4-nitro-1-pyridiniumolate | C7H8N2O3 | 详情 | 详情 | |
(XI) | 27247 | 4-bromo-3,5-dimethylpyridine | C7H8BrN | 详情 | 详情 | |
(XII) | 27248 | 3,5-dimethylisonicotinaldehyde | C8H9NO | 详情 | 详情 | |
(XIII) | 27249 | (3,5-dimethyl-4-pyridinyl)methanol | C8H11NO | 详情 | 详情 | |
(XIV) | 27250 | [2-cyclopropyl-7-[(3,5-dimethyl-4-pyridinyl)methoxy]-4-methoxy-1H-benzimidazol-1-yl]methyl 2-(trimethylsilyl)ethyl ether | C25H35N3O3Si | 详情 | 详情 |